BioAlliance first-half sales up at €198 million, R&D spending doubles

By Lisa Kerner

Charlotte, N.C., Sept. 27 - BioAlliance Pharma SA reported first-half net sales of €198 million, mainly from services it provided to Eurofins-VIRAlliance (EVI Inc). The company had €39 million for the comparable period in 2005, comprised of licensing fees from VIRalliance, its diagnostics subsidiary at the time.

Total first-half expenses, including research and development costs of €2.18 million, were up at €3.28 million versus €1.58 million for the first-half 2005.

Purchases and external expenses amounted to €3.28 million for the period, up from €1.58 million in 2005, due mainly to a rise in development costs in 2006.

BioAlliance booked net financial income of €226 million, compared with a net cost of debt of €123 million for the prior-year period.

At June 30, the company's net loss totaled €5.02 million, compared with a net loss of €3.2 million at June 30, 2005, again due primarily to R&D costs, most notably the phase 3 U.S. pivotal trial (Smiles) for Loramyc buccal tablets in HIV/cancer-related oropharyngeal candidiasis.

BioAlliance is an emerging specialty pharmaceutical company located in Paris.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.